Investor Presentaiton slide image

Investor Presentaiton

Screening Early Disease Detection Minimal Residual Disease Recurrence Detection & Surveillance Therapy Selection Advanced Cancer Care >120M Average-Risk Individuals Do I have cancer? GUARDANT™ >15M Early-Stage Patients and Survivors Cancer Detection Surgery +/- Adjuvant Do I still have cancer? >700K Advanced Cancer Patients INVESTOR 20 DAY 23 Recurrence 1st Line Tx 2nd Line Tx +TX Has my cancer returned? Am I responding to therapy? What kind of therapy is best for me? Shield™ LDT assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods. The Shield assay is a screening assay and not a replacement for a diagnostic colonoscopy. AACR Study, Cancer Prev Res (2020) 13 ACS Cancer Treatment & SurvivorshipFacts & Figures 2019-2021 American Cancer Society Cancer Facts and Statistics; SEER 11
View entire presentation